The company invites visitors to booth #1949 to discuss its mission and clinical programs

Sparrow Pharmaceuticals, an emerging, clinical-stage biopharmaceutical company developing novel, targeted therapies to address unmet needs in both endocrinology and rheumatology, will present the rationale that its lead candidate and HSD-1 inhibitor, SPI-62, is predicted to be associated with limited adrenal insufficiency risk in Cushing’s syndrome during a poster session at the Endocrine Society (ENDO) 2023 Annual Conference. The meeting will be held in-person from June 15-18, 2023 in Chicago, IL.

• Presentation title: Intracellular Cortisol Control: An Approach to Reduce Cushing’s Syndrome Morbidity With Minimal Adrenal Insufficiency Risk?
• Presenters: Frank S. Czerwiec, MD, PhD, Chief Medical Officer at Sparrow Pharmaceuticals; David A. Katz, PhD, Chief Scientific Officer, Sparrow Pharmaceuticals; Paul M. Stewart, MD, FRCP, FMedSci, University of Leeds, UK
• Presentation number: SAT-281
• Session Category: P71 - Clinical Adrenal & Pituitary: Adrenal Basic Science/Animal Models
• Date: Saturday, June 17, 2023 at 1:00pm-2:00pm CT

Sparrow is also available to connect with attendees at the company’s booth (#1949) during regular exhibit hours to learn more about Sparrow’s mission and clinical programs.

SPI-62 is a potent HSD-1 inhibitor in clinical development for treatment of Cushing’s syndrome and autonomous cortisol secretion, and as adjunctive therapy to prednisolone in polymyalgia rheumatica. In prior Phase 1 and Phase 2 clinical trials, SPI-62 was associated with maximal liver, adipose, and brain HSD-1 inhibition at generally well tolerated doses.

To learn more about Sparrow Pharmaceuticals SPI-62, visit www.sparrowpharma.com.

About Sparrow Pharmaceuticals

Sparrow Pharmaceuticals was founded to spare patients the ravages of steroids. Leveraging underappreciated scientific insights into glucocorticoid biology, the company is working to provide better treatment options for serious disorders of hypercortisolism, and to revolutionize the treatment of autoimmune and inflammatory conditions. Its lead product, SPI-62, is an oral, small molecule, novel therapeutic treatment designed to target the source of active intracellular glucocorticoids in key tissues.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230608005064/en/